

RECEIVED
DEC 22 2003
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Jane C. Hirsh, Kamal K. Midha, Mark Hirsh, and Whe-Yong Lo

Serial No.: 10/015,930

Art Unit: 1615

Filed: November 30, 2001

Examiner: Susan T. Tran

For: *PHARMACEUTICAL COMPOSITIONS FOR COMPRESSED ANNULAR TABLET
WITH MOLDED TRITURATE TABLET FOR BOTH INTRAORAL AND ORAL
ADMINISTRATION*

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicants submit a Supplemental Information Disclosure Statement, including two (2) pages of Form PTO-1449, and copies of the eighteen (18) documents cited therein.

The Commissioner is hereby authorized to charge \$180.00, representing the fee required under 37 C.F.R. §1.17(p) for an Information Disclosure Statement filed after a first Office Action on the merits under 37 C.F.R. §1.97(c), to Deposit Account No. 50-1868. It is believed that no additional fees are required with this submission. However, should a fee be required, the Commissioner is hereby authorized to charge any fees to Deposit Account No. 50-1868.

12/18/2003 HDEMESS1 00000040 501868 10015930
02 FC:1806 180.00 DA

U.S.S.N.: 10/015,930
Filed: November 30, 2001
SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

U.S. Patents

<u>Number</u>	<u>Publication Date</u>	<u>Patentee</u>	<u>Class/Subclass</u>
2001/0002999	06-07-2001	Neuser, et al.	424/464
4,139,589	02-13-1979	Beringer, et al.	264/250
4,322,433	03-30-1982	Leslie, et al.	424/298
4,661,492	04-28-1987	Lewis, et al.	514/282
5,053,032	10-01-1991	Barclay, et al.	604/892.1
5,368,588	11-29-1994	Bettinger, et al.	604/891.1
5,407,686	04-18-1995	Patel, et al.	424/468
5,609,884	03-11-1997	Desai	424/468
5,702,723	12-30-1997	Griffin	424/463
6,372,255	04-16-2002	Saslowski, et al.	424/473

Foreign Documents


<u>Number</u>	<u>Publication Date</u>	<u>Patentee</u>	<u>Country</u>
2 772 615	06-25-1999	Lipha	FR
0 584 594	03-02-1994	Gergely Gerhard	EP
1 044 680	10-18-2000	Beecham Pharmaceuticals	EP
1 112 737	07-04-2001	Hennig Arzneimittel GMBH	EP
800 973	09-03-1958	Sterling Drug Inc.	GB
WO 98/46235	06-07-2001	Bayer Aktiengesellschaft	PCT
WO 00/35296	06-22-2000	W.M. Wrigley Jr. Company	PCT
WO 01/37814	05-31-2001	Robert Gordon University	PCT

U.S.S.N.: 10/015,930
Filed: November 30, 2001
SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicants invite the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicants are of the opinion that their claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,


Patrea L. Pabst
Reg. No. 31,284

Dated: December 12, 2003


HOLLAND & KNIGHT LLP
One Atlantic Center
1201 West Peachtree Street, N.E.
Suite 2000
Atlanta, Georgia 30309-3400
404-817-8473
FAX 404-817-8588
www.hklaw.com

U.S.S.N.: 10/015,930
Filed: November 30, 2001
SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

Certificate of Mailing under 37 CFR §1.8(a)


I hereby certify that this Supplemental Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: December 12, 2003


Jean Hicks

1440825_v1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete if Known	
 INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/015,930
		Filing Date	November 30, 2001
		First Named Inventor	Jane C. Hirsh
		Group Art Unit	1615
		Examiner Name	Susan T. Tran
Sheet 1 of 2	Attorney Docket Number	CP 104	

U.S. PATENT DOCUMENTS					
Examiner Initials *	Cite No. ¹	US Patent Document		Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
		2001/0002999		Neuser, et al.	06-07-2001
		4,139,589		Beringer, et al.	02-13-1979
		4,322,433		Leslie, et al.	03-30-1982
		4,661,492		Lewis, et al.	04-28-1987
		5,053,032		Barclay, et al.	10-01-1991
		5,368,588		Bettinger, et al.	11-29-1994
		5,407,686		Patel, et al.	04-18-1995
		5,609,884		Desai	03-11-1997
		5,702,723		Griffin	12-30-1997
		6,372,255		Saslawski, et al.	04-16-2002

FOREIGN PATENT DOCUMENTS						
Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office. ³	Number ⁴	Kind Code ⁵ (if known)		
		FR	2 772 615		Lipha	06-25-1999
		EP	0 584 594		Gergely Gerhard	03-02-1994
		EP	1 044 680		Beecham Pharmaceuticals	10-18-2000
		EP	1 112 737		Hennig Arzneimittel GMBH	07-04-2001
		GB	800 973		Sterling Drug Inc.	09-03-1958
		PCT	WO 98/46235		Bayer Aktiengesellschaft	06-07-2001

Examine Signature		Date Considered	
-------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.


¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known		
				Application Number	10/015,930	
				Filing Date	November 30, 2001	
				First Named Inventor	Jane C. Hirsh	
				Group Art Unit	1615	
				Examiner Name	Susan T. Tran	
Attorney Docket Number	CP 104					
Sheet	2	of	2			

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examine Signature		Date Considered	
----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO:** Assistant Commission for Patent, Washington, DC 20231.